Clinician’s Brief spotlights practical OA pain management

Clinician’s Brief has published a sponsored Partner Podcast, “Practical Advice on Managing Osteoarthritis Pain With Dr. Downing,” featuring pain specialist Dr. Robin Downing in a discussion on canine osteoarthritis, pain, inflammation, and treatment options. The episode lands as osteoarthritis management keeps evolving beyond a single-drug mindset, with current guidance emphasizing multimodal care and individualized plans that can include NSAIDs, anti-nerve growth factor monoclonal antibodies, rehabilitation, weight management, and client education. AAHA’s 2022 pain management guidelines explicitly call for multimodal treatment and regular reassessment, while more recent canine OA literature continues to position both NSAIDs and anti-NGF monoclonal antibodies as first-line analgesic options in appropriate cases. (cliniciansbrief.com)

Why it matters: For veterinary professionals, the value here is practical framing rather than a new regulatory event or label change. OA remains one of the most common chronic pain conditions in dogs, and treatment decisions increasingly involve balancing efficacy, monitoring burden, comorbidities, adverse-event risk, pet parent preferences, and access to rehabilitation or long-term follow-up. Recent comparative data published in Frontiers in Veterinary Science found bedinvetmab performed similarly to meloxicam over 56 days in client-owned dogs, with fewer reported adverse events in that small study, underscoring why case selection and ongoing monitoring matter more than one-size-fits-all algorithms. (aaha.org)

What to watch: Expect more discussion around how practices sequence NSAIDs, monoclonal antibodies, disease-modifying options, and rehab-based support as new comparative studies and sponsored education continue to shape everyday OA protocols. (cliniciansbrief.com)